ATI-50002
Development of ATI-50002 for alopecia areata was discontinued by Aclaris Therapeutics.
A topical JAK 1/3 inhibitor taken through alopecia areata and pattern loss, and registered in neither since 2019.
This programme is no longer being actively pursued.
- Developed by
- Aclaris Therapeutics
- Current phase
- Discontinued
- Mechanism
- JAK inhibitor
- Indications
- Alopecia areata, Androgenetic alopecia
- Also known as
- ATI-502, ATI50002
- Last public activity
- December 2020
- Copy last reviewed
- September 2026
- Record confidence
- Medium
Development stopped.
Calms the immune attack on the follicle by blocking JAK signalling - the class that transformed alopecia areata.
A research record, not medical advice: being listed here says nothing about whether a treatment works or whether it is right for you. Talk to a dermatologist about your own case.
How it is meant to work
A topical solution of a JAK 1/3 inhibitor, trialled as ATI-502 in alopecia areata — including an eyebrow-loss study — and separately in androgenetic alopecia.
Why it matters
The second topical JAK in this register to run out of road, and for a different reason from delgocitinib: in the alopecia areata Phase 2, Aclaris reported that high rates of disease resolution in the vehicle arm left no superiority to show, the vehicle arm in fact doing numerically better. The open-label androgenetic alopecia study, 31 patients, was reported by the sponsor as positive, with a gain of 8.6 hairs/cm² at six months, and a dose-ranging trial planned for 2020 was never registered. Results are posted on ClinicalTrials.gov for both programmes. In August 2019 Aclaris said it would seek a partner to develop ATI-502 further; none has been announced, which is why this row is discontinued at MEDIUM rather than HIGH.
Development history
- Phase 2
First Phase 2 trial on record: NCT03354637 — A Study of ATI-50002 Topical Solution for the Treatment of Alopecia Areata
ClinicalTrials.gov ↗
Registered trials
Pulled automatically from ClinicalTrials.gov. Matching is by name and development code, so occasional gaps are possible — tell us if you spot one.
ATI-502 Topical Solution for the Treatment of Alopecia Areata (AA), Alopecia Universalis (AU) and Alopecia Totalis (AT)
Aclaris Therapeutics, Inc. · n=56 · January 2019
Open Label Study of ATI-50002 Topical Solution Administered to Adult Subjects With Eyebrow Loss Due to Alopecia Areata
Aclaris Therapeutics, Inc. · n=1 · April 2018
A Study in Male and Female Subjects With Androgenetic Alopecia Treated With ATI-50002 Topical Solution
Aclaris Therapeutics, Inc. · n=31 · March 2018
Safety and Pharmacokinetic Study of ATI-50002 in Subjects With Alopecia Universalis (AU) and Alopecia Totalis (AT)
Aclaris Therapeutics, Inc. · n=11 · December 2017
A Study of ATI-50002 Topical Solution for the Treatment of Alopecia Areata
Aclaris Therapeutics, Inc. · n=129 · November 2017
Listing a trial is not a recommendation to join one. Eligibility, risks and costs vary enormously — discuss any trial with your own doctor first.
Sources
- ATI-50002 topical solution in adults with eyebrow loss due to alopecia areata — results posted — ClinicalTrials.gov
- ATI-50002 topical solution in androgenetic alopecia — results posted — ClinicalTrials.gov
- A Study of ATI-50002 Topical Solution for the Treatment of Alopecia Areata (terminated, primary endpoint not met) — ClinicalTrials.gov
- Aclaris Therapeutics second quarter 2019 results and business strategy update (partner sought for ATI-502) — Company release, August 2019
- Aclaris Therapeutics announces Phase 2 clinical trial of ATI-502 topical in patients with alopecia areata did not meet endpoints — Company release, June 2019
- Aclaris Therapeutics announces positive 6-month results from a Phase 2 open-label trial of ATI-502 topical in androgenetic alopecia — Company release, June 2019
Related programmes
Other programmes in the register with the same mechanism: JAK inhibitor.
Cite this page
Hair Pipeline, "ATI-50002 — development record", hairpipeline.com/pipeline/ati-50002